✨ Free AI Report
ProKidney Corp.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research ProKidney Corp.
Company Research

ProKidney Corp.: Business Overview, Financials & Competitive Analysis

ProKidney Corp. scores 7/10 on the AskCyborg Cyborg Score (Strong). ProKidney offers a buy opportunity due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and sufficient cash runway. The company has seen significant volatility following encouraging Phase 2 clinical trial outcomes for its REGEN-007 study. 4 analysts recommend buying the stock, while 1 suggest selling.

What is ProKidney Corp.'s industry? ProKidney Corp. (prokidney.com) operates in Biotechnology / Cell Therapy / Nephrology. AskCyborg classifies ProKidney Corp. under Biotechnology / Cell Therapy / Nephrology in its company registry.

ProKidney Corp. is a clinical-stage biotechnology company that develops a cell therapy platform for the treatment of multiple chronic kidney diseases. The company develops therapies that repair and restore diseased ki...

7/ 10Strong

Cyborg Score thesis

ProKidney offers a buy opportunity due to promising Phase 2 data for rilparencel in advanced CKD, strong FDA alignment, and...

Read the full analyst-debate transcript →
Industry Biotechnology / Cell Therapy / Nephrology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest ProKidney Corp. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for ProKidney Corp.

AskCyborg analysts argue the bull and bear cases for ProKidney Corp. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
ProKidney Corp. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

ProKidney Corp. Overview

Pro stress-test →

ProKidney Corp. is a clinical-stage biotechnology company that develops a cell therapy platform for the treatment of multiple chronic kidney diseases. The company develops therapies that repair and restore diseased kidneys using a patient's own cells and may prevent or delay dialysis or transplant.

Strategic Profile

Pro stress-test →

Its lead product candidate, rilparencel, is in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. HC Wainwright & Co. initiated coverage with a Buy recommendation, positioning the company as a promising late-stage clinical player targeting a significant unmet medical need in nephrology.

Competitive Landscape

Pro stress-test →

ProKidney competes in the clinical-stage cell therapy space. Direct competitors include other autologous cell therapy developers targeting kidney disease, though ProKidney's lead candidate rilparencel appears positioned as a first-mover in this cell therapy indication with strong FDA alignment.

Industry Context

ProKidney Corp. operates in Biotechnology / Cell Therapy / Nephrology.

Key facts

Founded: 2015 · Headquarters: Winston-Salem, North Carolina · Employees: 204 · Revenue: null · Market cap: $0.761B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on ProKidney Corp..

  • Analyst HC Wainwright initiated coverage with a Buy recommendation and price target of $12.00, with average one-year price target revised to $6.85
  • Significant stock volatility following encouraging Phase 2 REGEN-007 trial outcomes for rilparencel in chronic kidney disease patients
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025HC Wainwright & Co. initiated coverage with Buy rating and $12.00 price target
  • November 2025Presented Phase 2 REGEN-007 results and strategic updates at healthcare conferences
  • +1 moreTrack every material event for ProKidney Corp. as it happens. Explore monitoring →
Get alerted when ProKidney Corp. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Advanced Renal TherapeuticsNephrology-focused biotech company→Kidney Disease Cell TherapyBiotech firm addressing kidney disease pathways→Cell Therapy PlatformsCellular therapeutics developer→

Compare ProKidney Corp. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ProKidney Corp. operates in Biotechnology / Cell Therapy / Nephrology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology / Cell Therapy / Nephrology research →
NEW · MCP server

Ask your AI assistant about ProKidney Corp.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ProKidney Corp. and its top competitor on Cyborg Score”
“What did ProKidney Corp. do this quarter?”
“Is ProKidney Corp. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does ProKidney Corp. do?+
ProKidney Corp. is a clinical-stage biotechnology company that develops a cell therapy platform for the treatment of multiple chronic kidney diseases. The company develops therapies that repair and restore diseased ki...
What is ProKidney Corp.'s Cyborg Score?+
ProKidney Corp. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ProKidney Corp.'s main competitors?+
Named competitors include Advanced Renal Therapeutics, Kidney Disease Cell Therapy, Cell Therapy Platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full ProKidney Corp. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ProKidney Corp. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ProKidney Corp. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score